Route explainer

Oral BPC-157: what survives the gut, and what nobody has measured

By the Decadewise team Education only The route question, not the dose question Last updated 9 August 2026 14 cited sources

Short answer

The molecule: BPC-157 is a synthetic chain of fifteen amino acids, sequence GEPPPGKPADDAGLV, and the fragment it copies was found in human gastric juice.

Why a capsule exists at all: the peptide is reported to resist gastric juice, and that single property is what every argument for swallowing it rests on.

What the property covers: the stomach, and nothing after it. A 2026 review counts four barriers between a swallowed peptide and the bloodstream, and records three of them as not determined for this one (Mateescu, 2026).

The missing measurement: no oral bioavailability figure exists for BPC-157 in any species. That review prints the value as unknown in its own comparison table.

The human record: FDA searched the literature for its July 2026 advisory committee and reported no study that gave BPC-157 to a person by mouth, and no human oral pharmacokinetic data.

The one registration: an oral phase 1 in 42 planned volunteers was posted in December 2015 and has never reported a result.

On this page

Short answer Why it is sold to swallow Does it survive acid? Where the claim comes from One barrier of four The human oral record Given by mouth to animals Swallowed against injected What is unsettled The safety picture How this is sourced Related pages The disclaimer

Why is BPC-157 sold as something you swallow?

The starting material: BPC-157 is the synthetic counterpart of a fragment of a larger protein isolated from human gastric juice, first described in the literature in 1993 (Sikiric, 1993). FDA gives its molecular weight as 1419.5 g/mol and its melting point as above 232 degrees Celsius.

The name carries the argument: the literature calls it the stable gastric pentadecapeptide, and both of those words point at the stomach. A molecule that came out of gastric juice and is reported to survive gastric juice reads, to anyone skimming, like a peptide built to be swallowed.

What is actually on sale: FDA's July 2026 briefing document records BPC-157 marketed in the United States as an ingredient in dietary supplement products formulated as oral capsules and tablets. The compounding nominations it was evaluating proposed capsules at 250 micrograms, 500 micrograms and 1 milligram, alongside an injection, a nasal spray, a rectal suppository and a transdermal cream.

What this page is, and what it is not: it is about the route. The evidence record source by source lives on the BPC-157 dosage guide, and the milligram to unit arithmetic lives on the BPC-157 calculator page, so neither is reopened here.

Does BPC-157 survive stomach acid?

What the stomach does to peptides: native gastric juice runs at pH 1 to 2 and carries pepsin at 0.5 to 1 mg per mL alongside hydrochloric acid and other proteases. Under those conditions most therapeutic peptides are rapidly hydrolyzed, which is why so few peptide drugs are given by mouth at all (Mateescu, 2026).

What is reported for this one: the same review calls resistance to that environment the compound's most distinctive physicochemical property, and the one most often cited to justify oral administration. Its stability table records gastric stability as high and enteric coating as not indicated, on the reasoning that a delivery system aimed at the gastric window is the mechanistically justified direction rather than one that skips the stomach.

How the number is usually written: a 2024 review from the group that discovered the peptide states that it is not destroyed in human gastric juice for more than 24 hours (Sikiric, 2024). That figure, and the sentence around it, is what the oral route is argued from across the literature.

The proposed reason is still a hypothesis: the 2026 review attributes the stability most plausibly to the run of prolines near the front of the sequence, which may fold into a polyproline II helix, a shape that shields the backbone from proteases. It then states that no circular dichroism, nuclear magnetic resonance or crystallography work has confirmed that shape, and that the peptide's three-dimensional solution structure is not described anywhere in the peer-reviewed literature.

What the stability claim is not: a claim about the powder in a vial. Shelf stability for a lyophilized peptide is a storage question, and survival in gastric juice is a digestion question, and the two are measured in completely different ways.

Where does the gastric-juice claim actually come from?

Why we followed it: the whole oral case for this compound rests on one property, so we chased the citation for that property back rather than repeating it.

The chain, one link at a time: the 2026 review supports the empirical stability with two references, and both of them are reviews, a 2025 literature and patent review (Józwiak, 2025) and the 2024 review quoted above. The 2025 review passes it on in turn to a 2022 review of muscle work by the discovering group (Staresinic, 2022), which states the same 24-hour figure and cites five further papers for it.

Where a primary record does surface: FDA's briefing document names a different and older one. It writes that BPC-157 was reported to be resistant to hydrolysis in gastric juice in vitro, and cites Veljaca, Chan and Guglietta 1995.

What that source is: one page in Pharmacological Research, volume 31, page 70, on the digestion of h-EGF, h-TGF alpha and BPC-15 in human gastric juice. Its record resolves through CrossRef, it is not indexed in PubMed, and the same item also appears as a meeting abstract in Gastroenterology at 108:A761.

What we are saying and what we are not: the property has a real empirical source and a regulator names it, so it is not a rumor. What we could not find is a full experimental paper with a method section behind it, and none of the four reviews in that chain cites the 1995 item, though one of them cites a different Veljaca report from 2002.

The biopharmaceutics of a swallowed peptide

Surviving the stomach is one barrier of four

The framework: the 2026 review sets out four barriers in sequence between a swallowed peptide and the bloodstream, and states that BPC-157's own properties address them unevenly. The table below is that review's reading of the literature to April 2026.

Four barriers, one of them addressed

Barrier	What the peptide's own properties do to it	What has actually been measured
Proteolysis in the stomach	reported resistance to gastric juice, which the review says removes this barrier and calls an asset shared by no other peptide candidate of comparable size	in vitro digestion work, which FDA traces to a one-page 1995 report
Proteolysis in the small intestine	nothing specific to this molecule is claimed	none. No data in simulated intestinal fluid, and none in ex vivo intestinal preparations
Permeability across the gut wall	nothing specific to this molecule is claimed	none. No Caco-2 assay and no PAMPA assay has been run on it
First-pass metabolism in the liver	nothing specific to this molecule is claimed	none. No hepatic extraction data exist

The four rows come from the 2026 review's stability table and its route-of-administration section (Mateescu, 2026). Three of them are recorded there as not determined.

Why size is the sticking point: at about 1419 daltons the molecule sits far above the roughly 500 dalton ceiling associated with easy passive diffusion through a cell, and transport between cells is generally treated as negligible above about 700 daltons. The intestinal peptide transporter PepT1 carries di- and tripeptides, so a fifteen-residue chain is the wrong shape for it, and transcytosis has never been investigated for this peptide.

Where the review lands: it offers a tentative reading of BCS Class III, high solubility and low permeability, and says in the same breath that this is a hypothesis for designing experiments rather than a classification, because no formal solubility or permeability data exist. The consequence it draws is that better dissolution would not help, and that permeability enhancement is the direction any oral formulation work would have to take.

The sentence that matters most: the review states that the proposition that gastric stability alone is sufficient for clinically meaningful oral bioavailability is unsupported by direct evidence, and that it is contradicted by the approved oral peptides, every one of which needed pharmaceutical or chemical intervention beyond intrinsic stability.

Has anyone taken oral BPC-157 in a trial?

The regulator's answer, from its own search: FDA's July 2026 briefing document states, in the safety conclusion on page 43, "We found no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal ROA." Three pages earlier, in the pharmacokinetics section, it states separately that it found no human pharmacokinetic data for BPC-157 after oral, subcutaneous, nasal or transdermal administration.

The one registration that exists: ClinicalTrials.gov holds NCT02637284, a randomized, quadruple-masked phase 1 in healthy volunteers, with PharmaCotherapia d.o.o. as lead sponsor and one listed site, Hospital Ángeles Tijuana in Tijuana, Mexico. Part 1a assigned volunteers to a single dose of one, three or six oral tablets each containing 1mg, against a matching placebo, and part 1b ran three tablets every 8 hours for two weeks.

What became of it: the record was first submitted on 15 December 2015 and first posted on 22 December 2015, its last update was submitted on 17 December 2015, and its overall status has read unknown ever since, with a last known status of active and not recruiting. No results are posted, and FDA reports that it could not find an associated published study either.

Two readings of one record, and they disagree: FDA describes it as a single phase 1 in healthy subjects in Mexico with no results posted, which is what the registry shows. The 2026 review describes the same identifier as registered in 2016 and terminated without results publication, and the registry supports neither the year nor the termination, so we print the registry and flag the difference.

What a dead registration is worth: a phase 1 that never reported is not evidence about the oral route in either direction. It is evidence that somebody once intended to answer the question and then stopped.

What happened when animals were given it by mouth?

Where the oral evidence actually lives: in rats, and usually in drinking water rather than by a measured swallow. The recurring design in this group of papers is that the peptide is given by two routes in the same experiment, and both are then reported to work.

Rodent studies that ran an oral arm beside another route

Source	What it gave by mouth	The other route in the same study	What the report says about the two
Xue, 2004	intragastric administration in rats, at 200, 400 and 800 nanograms per kilogram	intramuscular, at the same amounts	the only head-to-head statement in this group: the intramuscular effect was better than the intragastric one, and the effective amount by injection was the lower of the two
Klicek, 2008	in drinking water, at 10 micrograms per kilogram or 10 nanograms per kilogram	once-daily intraperitoneal, same two amounts	healing of the colocutaneous fistula is reported as accelerated by either route, with no difference drawn between them
Sever, 2009	in drinking water at 12mL per rat per day, at 10 micrograms per kilogram or 10 nanograms per kilogram	once-daily intraperitoneal	weight gain above preoperative values is reported for the short bowel model with therapy given both by mouth and parenterally
Cerovecki, 2010	in drinking water at 0.16 micrograms per mL, 12mL per day per rat	intraperitoneal, and a topical cream at the injury	the transected ligament is reported to improve on all three routes, each given alone and without a carrier
Ilic, 2011	in drinking water at 0.16 micrograms per mL and 0.16 nanograms per mL	intraperitoneal, at 10 micrograms per kilogram and 10 nanograms per kilogram	the antagonism of diclofenac toxicity is reported as strongly effective by either route

Every figure in this table was read from the study's own abstract on PubMed. The amounts belong to those rats and to those models, and no published work converts any of them to a human figure.

FDA read the same animal work and added a caveat: on the fistula study and on the diclofenac study it records that a dose-response relationship could not be established, because the two amounts reduced the lesions to the same extent. A thousandfold difference in the amount making no difference to the result is not what a working dose-response curve looks like.

The interpretation problem the review names: an effect seen in the gut after an oral dose can mean the intact peptide acted directly on the mucosa where it was delivered, or it can mean the peptide crossed into the circulation and acted from there. Nothing in this group of studies separates the two, and the review calls that the most consequential ambiguity in the oral literature on this compound.

Why the drinking-water design makes it harder still: a concentration in a water bottle consumed across a day is not a dose taken at a time point, so these experiments cannot produce the absorption curve the route question actually needs.

Is a swallowed amount the same as an injected one?

The short version: nobody knows, because the factor that would connect them has never been measured in any species.

The number that is missing: the 2026 review's comparison table prints the oral bioavailability of BPC-157 as unknown. In the same table it gives oral semaglutide at 0.4 to 1 percent with an absorption enhancer, cyclosporine at about 30 percent, and oxytocin and desmopressin each below 1 percent, which is the span those four approved products occupy once somebody has done the work of measuring it.

What has been measured, and by which route: the first formal pharmacokinetic study of this peptide gave it intravenously and intramuscularly to rats and beagle dogs, reporting an elimination half-life under 30 minutes, absolute intramuscular bioavailability of about 14 to 19 percent in rats and 45 to 51 percent in dogs, and excretion in urine and bile (He, 2022). It ran no oral arm at all, which is why the review that cites it still calls the oral figure absent.

What the gap costs a regulator: FDA writes that studies establishing the absolute bioavailability of BPC-157 by the intramuscular route and by the nominated routes were not identified, so it is not possible to use the intramuscular no-observed-adverse-effect levels to estimate the levels for those routes. An agency with the whole literature in front of it could not carry a number from an injection across to a capsule, and the reader of a capsule label is in the same position, only without the literature.

One thing the oral route does have going for it: FDA writes that the inherent immunogenicity risk of BPC-157 given orally is likely to be low, and reserves the sharper version of that concern for the injected and nasal routes. That is a statement about one risk class, not a verdict on the route, and the same document raises impurity concerns that apply whichever way the peptide goes in. The routes actually used in the published human studies are set out beside their sources on how peptide injections are administered.

What the oral record does not settle

The gaps we can name on this route:

Absorption. No oral bioavailability figure exists for BPC-157 in any species, under fasting or fed conditions, so there is no number to scale anything from.
The intestine. No stability data in simulated intestinal fluid or in ex vivo intestinal tissue has been published, so what the peptide meets after the stomach is unmeasured.
The gut wall. No Caco-2 or PAMPA permeability assay has been run, which is why the BCS Class III reading is offered as a hypothesis and not as a classification.
The liver. No hepatic extraction data exist, so the share of anything absorbed that survives the first pass is unquantified.
Local against systemic. The rodent oral results are compatible with direct action on the gut lining and with absorption into the circulation, and no published experiment separates the two.
Humans. As of FDA's July 2026 evaluation, no published study has given BPC-157 to a person by mouth, and the one registered oral trial has posted nothing in more than a decade.
The contents of the capsule. What a certificate of analysis does and does not test is its own question, taken apart on how to read a peptide COA, and FDA notes that most certificates it found for the free base carry purity results only.

No approved product containing BPC-157 exists in any country, which FDA states plainly in its July 2026 evaluation, and no pharmaceutical-grade oral formulation of it has been developed or validated.

The safety picture, from the record

What the record supports about the oral route: less than people assume, in both directions. FDA states that it identified no nonclinical pharmacokinetic or toxicology studies delivered by the nominated oral route, and that without an absolute bioavailability figure for that route it cannot translate the intramuscular no-adverse-effect levels into oral ones, which is the arithmetic every safety margin is built from. It also states that the inherent immunogenicity risk is likely lower by mouth than by injection, and separately that it is concerned about peptide-related impurities whichever route is used. The 2026 review adds that human safety data for this compound come from a small number of studies, none of them oral. So the honest reading is neither that swallowing it is safe nor that it is dangerous: the studies that would answer either way have not been run. Whether any of this applies to one person is a question for a doctor with their labs in hand, not for this page.

How this page is sourced

Primary documents wherever one exists: the physicochemical and formulation material comes from the 2026 review, read in full on PubMed Central rather than from its abstract; the regulatory material from FDA's July 2026 briefing document, downloaded as a PDF and read directly; the registration from the ClinicalTrials.gov record, pulled through the registry's own API; and every animal figure from that study's own abstract.

The searches behind the absence statements, so anyone can rerun them: we searched Europe PMC on 9 August 2026, HTTP 200, for the query ("BPC 157" OR "BPC-157") AND ("simulated gastric fluid" OR "simulated intestinal fluid" OR "pepsin"), which returned 8 records, none of them an experimental stability assay of this peptide in gastric or intestinal fluid. Two further Europe PMC searches the same day, both scoped to abstracts, returned 33 records for the compound alongside "drinking water" and 30 for the compound alongside intragastric, gavage, perorally or orally, and the five studies in the table above were drawn from those two sets.

What we could not do, stated plainly: we did not read the 1995 Veljaca item itself. Its DOI resolves to the publisher at HTTP 200 and CrossRef returns its authors, journal, volume and page, but the one page of text sits behind a paywall, so we report what FDA says it reports and what its own record says it is, and nothing more.

A disagreement we are leaving in view rather than smoothing over: the 2026 review and the registry do not tell the same story about NCT02637284, differing on both the year it was registered and on whether it was terminated. We print the registry because it is the primary record, and we name the difference because a reader checking one source against the other deserves to find it here first.

Fourteen sources: eleven journal articles, each carrying both a DOI and a PubMed ID, one FDA advisory-committee briefing document, one trial registry record, and one 1995 conference report that carries a DOI, has no PubMed ID, and exists only as a single page.

The standard: the full sourcing and citation-verification standard for this site, including who checks a page before it ships, lives on the methodology page.

Last reviewed: 9 August 2026.

1
Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. The four-barrier framework, the BCS Class III hypothesis, the stability table and the comparison table are in its sections 4 and 5, read in full at PubMed Central on 9 August 2026, HTTP 200. doi:10.3390/pharmaceutics18050625. PMID 42198317.
2
U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, 23 to 24 July 2026: Evaluation of BPC-157-Related Bulk Drug Substances. The nominated oral capsule strengths are on page 9, the physicochemical figures on page 13, the rat oral studies and the dose-response caveat on pages 30 and 31, the Veljaca 1995 attribution and the animal half-lives on page 32, the absence of human oral pharmacokinetic data on page 40, the description of NCT02637284 on page 42, and the statement that no study administered it to humans by the oral route on page 43. Retrieved as a PDF on 9 August 2026, HTTP 200.
3
Veljaca M, Chan K, Guglietta A. Digestion of h-EGF, h-TGF alpha, and BPC-15 in human gastric juice. Pharmacol Res. 1995;31:70. A single-page conference report, not indexed in PubMed, and the source FDA names for in vitro resistance to gastric hydrolysis. Record confirmed through CrossRef on 9 August 2026, HTTP 200. doi:10.1016/1043-6618(95)86539-x. The same item also appears as a meeting abstract in Gastroenterology 1995;108:A761, doi:10.1016/0016-5085(95)27355-7.
4
Sikiric P, Boban Blagaic A, Strbe S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. The statement that the peptide is not destroyed in human gastric juice for more than 24 hours is in its introduction. doi:10.3390/ph17040461. PMID 38675421.
5
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. Its section 2 carries the stability sentence and attributes it to the 2022 muscle review below. doi:10.3390/ph18020185. PMID 40005999.
6
Staresinic M, Japjec M, Vranes H, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3221. The third link in the citation chain for the 24-hour gastric-juice figure, which it states in its introduction and supports with five further references. doi:10.3390/biomedicines10123221. PMID 36551977.
7
Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. The original description of the parent protein and its gastric-juice origin. doi:10.1016/0928-4257(93)90038-u. PMID 8298609.
8
ClinicalTrials.gov. PCO-02, Safety and Pharmacokinetics Trial, identifier NCT02637284. Phase 1, randomized, quadruple-masked, parallel assignment, 42 participants estimated, lead sponsor PharmaCotherapia d.o.o., collaborator and sole listed site Hospital Ángeles Tijuana, Tijuana, Mexico. Oral tablets of 1mg, single doses of one, three or six tablets in part 1a and three tablets every 8 hours for two weeks in part 1b. First submitted 15 December 2015, first posted 22 December 2015, last update submitted 17 December 2015, overall status unknown with a last known status of active and not recruiting, no results posted. Retrieved through the registry v2 API on 9 August 2026, HTTP 200.
9
He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. The half-life, the intramuscular bioavailability figures and the urinary and biliary excretion are in its abstract; the study administered the peptide intravenously and intramuscularly only. doi:10.3389/fphar.2022.1026182. PMID 36588717.
10
Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1036. The intragastric against intramuscular comparison, and the statement that the injected route was the better and lower-amount one, are in its abstract. doi:10.3748/wjg.v10.i7.1032. PMID 15052688.
11
Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. 2008;108(1):7-17. doi:10.1254/jphs.fp0072161. PMID 18818478.
12
Sever M, Klicek R, Radic B, et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci. 2009;54(10):2070-2083. doi:10.1007/s10620-008-0598-y. PMID 19093208.
13
Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. The per-oral drinking-water concentration and the three routes compared are in its abstract. doi:10.1002/jor.21107. PMID 20225319.
14
Ilic S, Drmic D, Zarkovic K, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci. 2011;88(11-12):535-542. doi:10.1016/j.lfs.2011.01.015. PMID 21295044.

Around this page: four neighboring pages that carry the questions this one deliberately does not answer.

BPC-157 dosage guide: the evidence record, every amount a named source administered, with the source in its own column.
BPC-157 dosage calculator: the tool page, where the milligram to unit conversion is worked and nothing is recommended.
What is a lyophilized peptide: what the powder is, and why shelf stability and digestive stability are different measurements.
How peptide injections are administered: the routes named in approved labels and published trials, beside the one this page is about.

The briefing: route explainers like this one ship in The Decadewise briefing before they land anywhere else.

The disclaimer

Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice. It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.